MindWalk Holdings (HYFT) Times Interest Earned (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Times Interest Earned of $0.0 for Q2 2026, up 164.85% year-over-year from $0.0 in Q2 2025, and up 164.85% quarter-over-quarter from -$0.0 in Q2 2025.
MindWalk Holdings (HYFT) Times Interest Earned (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Times Interest Earned for 7 consecutive years, with $0.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Times Interest Earned rose 164.85% year-over-year to $0.0; the TTM figure through Apr 2026 stood at $0.02 (up 100.15% YoY), while the FY2026 annual figure was -$0.08, down 226546.53% from the prior year.
- Times Interest Earned advanced to $0.0 in Q2 2026 per HYFT's latest filing, from -$0.0 in the prior quarter.
- Across five years, Times Interest Earned topped out at $30.13 in Q2 2023 and bottomed at -$127.49 in Q3 2022.
- Historically, Times Interest Earned has averaged -$25.27 across 5 years, with a median of -$2.19 in 2022.
- Annual changes were most pronounced in 2022 — Times Interest Earned plunged 290494.35% — and 2023, when it jumped 788.03%.
- MindWalk Holdings' Times Interest Earned stood at -$0.0 in 2022, then soared by 101245669.65% to $30.13 in 2023, then sank by 284.37% to -$55.55 in 2024, then surged by 100.0% to -$0.0 in 2025, then jumped by 164.85% to $0.0 in 2026.
- Business Quant data shows HYFT's Times Interest Earned at $0.0 in Q2 2026, -$0.0 in Q2 2025, and -$55.55 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -55.73 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 0.00 |
| Apr 30, 2025 | 0.00 |
| Apr 30, 2024 | -55.55 |
| Apr 30, 2023 | 30.13 |
| Oct 31, 2022 | 0.00 |
| Jul 31, 2022 | -127.49 |
| Apr 30, 2022 | -4.38 |
| Jan 31, 2022 | -44.86 |
| Oct 31, 2021 | -34.22 |
| Jul 31, 2021 | -0.04 |
| Apr 30, 2021 | 37.88 |
| Jan 31, 2021 | -13.86 |
| Oct 31, 2020 | -16.53 |
| Jul 31, 2020 | -5.73 |